[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche's Corporate Executive CommitteeGlobeNewsWire • 02/02/23
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 productsGlobeNewsWire • 02/02/23
European Commission approves label expansion of Roche's Hemlibra to include people with moderate haemophilia A in the EUGlobeNewsWire • 02/01/23
Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart DiseasePRNewsWire • 01/30/23
Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variantGlobeNewsWire • 01/26/23
[Ad hoc announcement pursuant to Art. 53 LR] Roche's Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trialGlobeNewsWire • 01/19/23
Genentech's Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III TrialBusiness Wire • 01/19/23
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and aboveGlobeNewsWire • 01/12/23
FDA grants priority review to Roche's bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphomaGlobeNewsWire • 01/06/23
FDA Grants Priority Review to Genentech's Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell LymphomaBusiness Wire • 01/06/23
Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with GenentechBusiness Wire • 01/05/23
FDA approves Roche's Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphomaGlobeNewsWire • 12/23/22